(rSO₂) during hypothermia after birth asphyxia. Contrary to earlier reports,^{2–4} rSO₂ was not suitable to study the effects of additional neuroprotective therapies. The authors postulated that the late timing of rSO₂ measurement contributed to this finding and that hypothermia could have equally slowed down cerebral metabolism (less O₂ utilization) in infants with and without reperfusion injury. We may have an alternative explanation for the divergent results. The range of rSO₂s during hypothermia in asphyxiated infants with adverse outcome measured with the small adult sensor of Somanetics (Troy, MI) is between 82% and 95%.^{2–4} The highest value of rSO₂ is limited at 95% (set by manufacturer). Since the neonatal sensor of Somanetics read rSO₂ values 10% higher on average compared to the small adult Somasensor,⁵ this range has been compressed to between 92% and 95%. The authors do not mention the actual numbers of rSO₂ but it is possible that the use of the neonatal sensor may have contributed to the divergent results concerning efficacy of rSO₂ as a prognostic biomarker.

Author Response: Renee A. Shellhaas, John Barks, Ann Arbor, MI: Our Dutch colleagues highlighted an important point: the rSO₂ value depends on the sensor employed. Their data⁵ were published after ours went to press, but we cited a personal communication with Drs. Lemmers and Toet in our Discussion. A strength of our study was that we used a clinically available device (Invos 5100C, Somanetics Corporation). We also utilized the US Food and Drug Administration–approved neonatal cerebral and somatic sensors, which is the equipment most likely to be used clinically in an American NICU and in future clinical research. However, published articles do not

often list which sensor was utilized. Future near-infrared spectroscopy research must consistently report the exact equipment and sensor type.

In our study,¹ the mean cerebral rSO₂ immediately before and during rewarming was 81.9 ± 3.39 (somatic rSO₂ was 71.8 ± 7.15). The Dutch data demonstrated divergent cerebral rSO₂ and fractional cerebral tissue oxygen extraction values in the first 36 hours of life for those with adverse vs favorable outcome.⁴ However, the absolute differences decreased thereafter, with no significant difference at 60 hours, the timeframe most comparable to our study. Therefore, the combination of their and our data suggests that cerebral rSO₂ on the third day of life may not differentiate those destined for favorable or adverse outcomes.

© 2014 American Academy of Neurology

1. Shellhaas RA, Thelen BJ, Jayapalli R, et al. Limited short-term prognostic utility of cerebral NIRS during neonatal therapeutic hypothermia. *Neurology* 2013;81:249–255.
2. Toet MC, Lemmers PMA, van Schelven LJ, van Bel F. Cerebral oxygenation and electrical activity after birth asphyxia: their relation to outcome. *Pediatrics* 2006;117:333–339.
3. Ancora G, Maranella E, Grandi S, et al. Early predictors of short term neurodevelopmental outcome in asphyxiated cooled infants: a combined brain amplitude integrated electroencephalography and near infrared spectroscopy. *Brain Dev* 2013;35:26–31.
4. Lemmers PMA, Zwanenburg RJ, Benders MJ, et al. Cerebral oxygenation and brain activity after perinatal asphyxia: does hypothermia change their prognostic value? *Pediatr Res* 2013;74:180–185.
5. Dix LM, van Bel F, Baerts W, Lemmers PM. Comparing near-infrared spectroscopy devices and their sensors for monitoring cerebral oxygen saturation in the neonate. *Pediatr Res* 2013;74:557–563.

CORRECTION

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology

In the article “Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology” by A. Culebras et al. (*Neurology*[®] 2014;82:716–724), there was an error on page 720 of the print article and on pages 24 and 58 of the full-length article (see data supplement e-1) regarding the recommended dosage for apixaban. The text should read: “Apixaban 5 mg twice daily (if serum creatinine <1.5 mg/dL), or 2.5 mg twice daily if any 2 of the following criteria are present: serum creatinine >1.5 mg/dL and <2.5 mg/dL; body weight ≤60 kg; age ≥80 years.” The authors regret the error.

Neurology[®]

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology

Neurology 2014;82;1481

DOI 10.1212/WNL.0000000000000465

This information is current as of April 21, 2014

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/82/16/1481.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.